VasoMedical to Exhibit BIOX ECG Holter at Medical Fair Thailand 2013
Septemeber 6, 2013 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, announced today that the Company will attend Medical Fair Thailand from September 12-14 in Bangkok, Thailand to exhibit its BIOXTM ECG Holter products.
The sixth annual Medical Fair Thailand will be the largest and most significant medical and health exhibition in Thailand. Since 2003, Medical Fair Thailand has become an important platform for regional and international healthcare providers, medical suppliers, industry professionals, government bodies, hospital administrators, doctors and nurses to learn about the latest medical devices and trends. The most recent conference welcomed 328 exhibiting companies from 25 countries which included more than 5,500 attendees from all over the globe.
At the event, VasoMedical will showcase its BIOX ECG Holter and ambulatory blood pressure monitors. BIOX products, designed to minimize size and weight with an extended battery life, represent an extensive line of ambulatory monitoring devices for long term recording and analysis of ECG and blood pressure data. The unique BIOX Model 2301/2302 Combined 3- & 12-Channel ECG Holter and Ambulatory Blood Pressure monitors were the first and only combined ECG and Blood Pressure monitors to be U.S. FDA cleared.
“The healthcare sectors in Thailand and its neighboring countries are growing quickly, which makes Medical Fair Thailand a great forum for us to reach out to the Southeast Asian and international medical communities and introduce our latest technology to the area. At this event, the VasoMedical-BIOX team will showcase its BIOX ECG Holter products to continue to generate awareness and educate leading health professionals from around the world about the uses and advantages of BIOX ECG Holter and ambulatory blood pressure monitors,” said Larry Liebman, Vice President of Sales & Marketing at VasoMedical.
Liebman continued, “Ambulatory ECG and blood pressure data provide important information about incidental cardiovascular abnormalities that are often not observable during a visit to the physician's office, and are therefore extremely valuable for early diagnosis of cardiovascular diseases. We look forward to discussing the benefits of this technology with attendees from around the globe.”
VasoMedical will be located at Booth R20.
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at http://www.biox.com.cn/bioxen/default.asp.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.